Skip to content
Peptigraph home

AOD-9604 and Tirzepatide Together: What Is Known

AOD-9604 and Tirzepatide taken together: what each one is, how each is regulated, and what is known about combining them.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
HGH fragment analogNot FDA approved · research chemicalAOD-9604Fragment of human growth hormone studied only in animals; in rats, 19 days of oral treatment reduced body-weight gain by over 50%.[7]GLP-1 & metabolicGLP-1 / GIP dual agonistFDA approved (Mounjaro, Zepbound)TirzepatideFDA-approved dual GIP and GLP-1 receptor agonist; in a large trial, mean weight change at week 72 was -15.0% on 5-mg and -19.5% on 10-mg weekly doses.[14]GLP-1 & metabolic
Interaction notes

Timing, interactions and safety

Evidence for the combination

No studies tested these together (PubMed search: 0 results, 2 Oct 2026).

We have no sourced data on taking these two together. Ask the prescriber who manages both.
Each component

Side by side

Showing 12 of 14 fields where the two differ. Category, PCAC vote, Jul 2026 are the same or both unknown.

FieldAOD-9604Tirzepatide
ClassHGH fragment analogGLP-1 / GIP dual agonist
Also calledAODtirz, tirze, Mounjaro, Zepbound
FDA statusNot FDA approved · research chemicalFDA approved (Mounjaro, Zepbound)
WADAProhibited by WADA (S2.2.3)AOD-9604 is named as a growth hormone fragment in S2.2.3, prohibited at all times.Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it.
Anti-doping detection
  • AOD9604 can be detected in urine at 50 pg/mL; a stable serum metabolite may lengthen the detection window.PMID 25208511
  • Screening for a stable metabolite may allow a longer detection window (no duration was given).PMID 25208511
None reportedanti-doping literature, as of 2 Oct 2026
Half-lifeNo published half-life foundPubMed search, 2 Oct 2026approximately 5 dayssubcutaneous · FDA label (Mounjaro)
Evidence strengthAnimal evidence, 2 of 4Strongest: Annals of clinical and laboratory science 2015, PMID 26275694Human RCT evidence, 4 of 4Strongest: Arthritis & rheumatology 2026, PMID 41903163
Human studies we summarised0 human (0 randomized or controlled) of 4 summarised24 human (22 randomized or controlled) of 30 summarised
Typical study doses
Vial sizes sold2 mg, 5 mg, 10 mg5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 120 mg
US searches per month18,100 · +31% searches1,220,000 · +30% searches
Named in FDA warning letters, 2026Not in the letters we trackYes (24 Aug 2026; 31 Mar 2026)

What people search

  • aod 9604 with tirzepatide170/mo
  • aod 9604 and tirzepatide together50/mo
  • tirzepatide and aod 9604 together20/mo
  • tirzepatide and aod960410/mo
  • aod 9604 and tirzepatide10/mo

US monthly searches, Google Keyword Planner, Oct 2026. Shown so you can see which questions this page answers.

Sources

  1. 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  2. 2FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
  3. 3Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
  4. 4World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  5. 5Detection and in vitro metabolism of AOD9604.Drug testing and analysis · 2015PMID 25208511Accessed 2 Oct 2026
  6. 6Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model.Annals of clinical and laboratory science · 2015PMID 26275694Accessed 2 Oct 2026
  7. 7Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.Hormone research · 2000PMID 11146367Accessed 2 Oct 2026
  8. 8PubMed search: AOD9604[tiab] OR "AOD-9604"[tiab] OR "AOD 9604"[tiab] (22 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9These highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO. MOUNJARO ® (tirzepatide) Injection, for subcutaneous uFDA label (Mounjaro), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  10. 10Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026PMID 41903163Accessed 2 Oct 2026
  11. 11Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.Obesity (Silver Spring, Md.) · 2026PMID 41537305Accessed 2 Oct 2026
  12. 12Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.The New England journal of medicine · 2025PMID 40353578Accessed 2 Oct 2026
  13. 13PubMed search: ("AOD-9604"[tiab] OR AOD9604[tiab]) AND (tirzepatide[tiab] OR Mounjaro[tiab] OR Zepbound[tiab] OR LY3298176[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  14. 14Tirzepatide Once Weekly for the Treatment of Obesity.The New England journal of medicine · 2022PMID 35658024Accessed 2 Oct 2026

Found an error? Report a correction.